---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical presentation - signs and symptoms. Topics: Multisystem involvement: prevalence of comorbidities by organ system, Motor symptoms: loss of purposeful hand use, Motor symptoms: hand stereotypies, Motor symptoms: gait impairment and loss of ambulation, and 15 further topics. 19 evidence topics quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Multisystem involvement: prevalence of comorbidities by organ system

> “Neurological comorbidities had the highest prevalence, occurring in nearly all individuals with gastrointestinal and orthopaedic concerns almost as prevalent as neurological. With the exception of low bone mineral content which was relatively common, endocrine comorbidities were seen in only around one-third of patients. Although more prevalent compared with the general population, cardiac conduction abnormalities were the least common comorbidity in RTT.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “Of 6253 records screened, 148 studies met inclusion criteria, spanning 24 countries and participants aged 7 months to 37 years.”
> “Epilepsy prevalence ranged from 15.0% to 91.0%, scoliosis 8.9–100% and gastrointestinal dysfunction was common, including constipation (16.4–82.8%) and gastroesophageal reflux (15.8–100.0%).”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-2"></a>

### Motor symptoms: loss of purposeful hand use

> “Following the initial regression period, hand function continues to decline across the age spectrum in individuals with RTT.”

Source: [Neul et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10939125/)

> “Conversely, more than 70% of individuals had delays in ambulation (Table 2C) and nearly 100% had abnormalities in hand function (Table 2D), both in keeping with two of the four main diagnostic criteria for classic RTT.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-3"></a>

### Motor symptoms: hand stereotypies

> “HS were reported in 922 participants with classic RTT (100%), 73 with atypical severe RTT (97.3%), 74 with atypical mild RTT (96.1%), and 17 females with MECP2 mutations without RTT (34.7%).”
> “While hand function decreased over time, prevalence and frequency of HS remained relatively unchanged and high.”

Source: [Stallworth et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6556084/)

> “Hand stereotypies were reported in 11.4% of studies, with prevalence of 70.0–100.0%.”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-4"></a>

### Motor symptoms: gait impairment and loss of ambulation

> “More than 31% had delayed acquisition, and 8% had lost the previously acquired ambulation skill. In addition, nearly 34% had never acquired the ability to ambulate.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

> “Ambulation varies significantly among RTT patients, with prevalence ranging from 12.0% to 73.0% across eight different studies.”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-5"></a>

### Motor symptoms: dystonia, rigidity, and other movement abnormalities

> “Outside of the repetitive hand movements that are part of the main diagnostic criteria of typical RTT, additional movement abnormalities are found in 60%–80% involving varying combinations of dystonia, tremor, myoclonus, chorea and progressive limb rigidity with bradykinesia resembling parkinsonism.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “Six studies reported on the prevalence of dystonia ranging from 18.2% to 95.5%”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-6"></a>

### Communication symptoms: loss of spoken language and impaired nonverbal communication

> “Nearly all participants had delays in language development (Table 2F) and 90% had abnormalities in nonverbal communication (Table 2G), again reflecting significant difficulties in one of the main diagnostic features for classic RTT.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

> “The percentage of participants who lost previously gained skills ranged from 6.6% (Lift Head) to 88.6% (Words with Meaning).”
> “Similarly, within expressive language, nearly all participants gained early skills such as Cooing and Babbling, but less than 25% gained Spoken Phrases.”

Source: [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/)

<a id="topic-2.2.1.6-7"></a>

### Cognitive symptoms: intellectual disability

> “Intellectual disability is prevalent in 68.0–100.0% of patients according to different studies, while microcephaly is common, with prevalence ranging from 19.0% to 100.0% across ten studies.”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-8"></a>

### Neurological symptoms: epilepsy

> “While point prevalence of active seizures ranged from 30% to 44%, the estimated cumulative lifetime prevalence of epilepsy using Kaplan-Meier approached 90%.”

Source: [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/)

> “A total of 360 (60%) were reported to have seizures, including 315 (60%) classic and 45 (61%) atypical RTT. Physician assessment of the 602 indicated that 48% had seizures.”
> “A significant age impact for seizures was seen and seizures were infrequent before age 2 years.”

Source: [Glaze et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2836870/)

<a id="topic-2.2.1.6-9"></a>

### Autonomic symptoms: awake breathing abnormalities

> “Participants with classic or atypical severe RTT were more likely to have breathing dysfunction (nearly 100% over the lifespan) compared to those with atypical mild RTT (60-70%). Remission was common, lasting 1 year on average, with 15% ending the study in terminal remission.”

Source: [Tarquinio et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026556/)

> “In terms of respiratory function (Table 2H), nearly 50% presented evidence of significant breath‐holding or hyperventilation (or both), and more than 25% had some degree of abnormality.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-10"></a>

### Autonomic symptoms: cold hands and feet

> “About 60% had abnormal autonomic function (Table 2I) with cool or cold hands and/or feet.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-11"></a>

### Cardiac signs: QTc prolongation

> “Of the 613 participants with classic and atypical RTT who had EKG data, 18% had a borderline and 10% had an abnormal QTc interval.”

Source: [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/)

> “Mean QTc of the cohort was 422.6 msec, which did not exceed the normal values for age. 7/100 patients (7%) had QTc prolongation (>450 msec).”

Source: [Crosson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5444992/)

> “Finally, cardiac conduction abnormalities involving prolonged QT interval are seen in 10%–18%.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

<a id="topic-2.2.1.6-12"></a>

### Gastrointestinal symptoms: constipation, reflux, and biliary disease

> “In addition to the highly prevalent neurodevelopmental issues, gastrointestinal and orthopaedic comorbidities are both also quite prevalent, each reported in over 80% of individuals.”
> “The gastrointestinal issues primarily involve constipation but around 40% also have gastro-oesophageal reflux.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “GI manifestations affected 43.0% of 5940 patients, with increased prevalence in pediatric patients (45.6%) relative to adult patients (40.2%).”
> “Importantly, the prevalence of GI manifestations was likely underestimated in this study, as only those symptoms which resulted in a healthcare encounter were captured.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.1.6-13"></a>

### Oral and feeding symptoms: swallowing dysfunction and drooling

> “Impaired swallowing function has equal prevalence to epilepsy over the lifespan but becomes apparent at a younger age often manifesting in early childhood as prolonged feeding times, choking/gagging on food and/or aspiration of liquids.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

> “Among eight studies which reported on dysphagia and chewing problems, the prevalence ranged from 23.5% to 76.7%”
> “Drooling was also reported in five studies ranging from 39.2% to 92.9% among the patients”

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/)

<a id="topic-2.2.1.6-14"></a>

### Growth: deceleration of head growth and somatic growth failure

> “Mean growth in classic RTT decreased below that for the normative population at 1 month for head circumference, 6 months for weight, and 17 months for length. Mean BMI was similar in those with RTT and the normative population. Pubertal increases in height and weight were absent in classic RTT.”

Source: [Tarquinio et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3468773/)

> “Head growth (Table 1C) was normal in 27.6% and microcephalic by age 2 years in 28.6%.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

<a id="topic-2.2.1.6-15"></a>

### Endocrine signs: altered pubertal timing

> “The timing of secondary sexual characteristics is also frequently altered in RTT with early adrenarche or thelarche in a quarter and just under 20% with delayed menarche.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

<a id="topic-2.2.1.6-16"></a>

### Sleep symptoms: sleep disturbance and sleep-disordered breathing

> “Sleep problems were identified in over 80% of cases. The prevalence of night-time laughter decreased with age and the prevalence of reported night-time seizures and daytime napping increased with age.”

Source: [Young et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2527512/)

> “Six of thirteen participants had obstructive sleep apnea, which was worse during rapid eye movement (REM) sleep with associated hypoxemia and disruptions in sleep architecture.”

Source: [Peters et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354067/)

<a id="topic-2.2.1.6-17"></a>

### Behavioral symptoms: anxiety and internalizing behavior

> “Most participants with RTT (77.5%) had at least occasional anxious or nervous behavior.”

Source: [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/)

> “Behaviour disturbances occur in nearly all individuals with RTT across the lifespan with internalising behaviours such as anxiety or mood swings being much more common overall than externalising behaviours such as aggression, hyperactivity or self-injury which are seen in about 40% of individuals, almost always with onset before 3 years of age and which improve over time in contrast to the internalising behaviours.”

Source: [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/)

<a id="topic-2.2.1.6-18"></a>

### Pain: frequency, sources, and expression

> “Of the 44 families responding to the survey, 24% reported that their child had experienced pain on 8 or more days (> 1 week) in the previous 30 days (43% were unsure)”
> “Ninety percent of the individuals reported on with RTT did not use words for pain. The most frequent form of pain communication was facial expression (85%) and vocalization (82%, e.g., moan, cry).”
> “The most commonly reported pain source was gastrointestinal [GI] (66%)”

Source: [Symons et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3707000/)

<a id="topic-2.2.1.6-19"></a>

### Orthopaedic signs: scoliosis, hip displacement, and foot deformities

> “This meta-analysis found that approximately two in three girls with RTT develop scoliosis, one in two exhibit foot deformities and one in three experience hip displacement.”

Source: [Galán-Olleros et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39429113/)

> “Although scoliosis (Table 2E) was absent in greater than 50%, the appearance of abnormal curvature in nearly 35% as well as the evidence of surgical correction in 11.8% indicated nearly half having significant difficulties with spinal deformity.”

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
